Liver transplantation for viral hepatitis in 2015

World Journal of Gastroenterology

Volumn 22, Issue 4, 2016, Pages 1570-1581

  Ferrarese, Alberto ^a   Zanetto, Alberto ^a   Gambato, Martina ^a   Bortoluzzi, Ilaria ^a   Nadal, Elena ^a   Germani, Giacomo ^a   Senzolo, Marco ^a   Burra, Patrizia ^a   Russo, Francesco Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Antiviral therapy; Hepatitis b virus; Hepatitis C virus; Liver transplantation; Prophylactic therapy; Recurrence post Transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; BOCEPREVIR; CYCLOSPORIN; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; LAMIVUDINE; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; TELBIVUDINE; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE LIVER FAILURE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; DIARRHEA; FATIGUE; GRAFT SURVIVAL; HEADACHE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REINFECTION; RISK FACTOR; TREATMENT INDICATION; VACCINATION; VIRUS HEPATITIS; VIRUS REACTIVATION; ADVERSE EFFECTS; COMPLICATION; DISEASE COURSE; END STAGE LIVER DISEASE; GRAFT REJECTION; HEPATITIS B; HEPATITIS C; IMMUNOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; END STAGE LIVER DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 85015344215     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i4.1570     Document Type: Article

References (99)

1. World Health Organization. Hepatits B. Fact sheet No. 204. Available from: URL: http://wwwwhoint/mediacentre/facsheets/fs204/en2014.
2. García-Fulgueiras A, García-Pina R, Morant C, García-Ortuzar V, Génova R, Alvarez E. Hepatitis C and hepatitis B-related mortality in Spain. Eur J Gastroenterol Hepatol 2009; 21: 895-901 [PMID: 19357523 DOI:10.1097/MEG.0b013e328313139d].
3. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-207 [PMID: 18086507 DOI:10.1016/j.jhep.2007.09.010].
4. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, Burroughs A. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688 [PMID: 22609307 DOI:10.1016/j.jhep.2012.04.015].
5. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI:10.1016/j.jhep.2012.02.010].
6. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215 DOI:10.1056/NEJMoa033364].
7. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902 [PMID: 11451174].
8. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. Long-Term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834 [PMID: 11003630 DOI:10.1053/jhep.2000.17912].
9. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, Brosgart CL, Westland C, Arterbrun S, Deray G. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 1153-1158 [PMID: 15327411 DOI:10.1111/j.1523-1755.2004.00866.x].
10. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178 [PMID: 18053766 DOI:10.1016/S1473-3099(07)70264-5].
11. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-1305 [PMID: 19619264 DOI:10.1111/j.1478-3231.2009.02085.x].
12. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 162-170 [PMID: 16673294 DOI:10.1055/s-2006-939758].
13. Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-2006 [PMID: 19937695 DOI:10.1002/hep.23346].
14. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72 [PMID: 21254162 DOI:10.1002/hep.23952].
15. Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 [PMID: 15880505 DOI:10.1002/hep.20704].
16. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI:10.1002/hep.21513].
17. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727 [PMID: 12198698].
18. Buti M, Oyagüez I, Lozano V, Casado MA. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: A systematic review. Pharmacoeconomics 2013; 31: 63-75 [PMID: 23329593 DOI:10.1007/s40273-012-0009-2].
19. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430 [PMID: 20049753 DOI:10.1002/hep.23327].
20. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22504333 DOI:10.1016/j.jhep.2012.02.033].
21. Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014; 147: 152-161 [PMID: 24583062 DOI:10.1053/j.gastro.2014.02.033].
22. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, Alessandria C, Franchello A, Salizzoni M, Rizzetto M. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-409 [PMID: 15776431 DOI:10.1002/lt.20402].
23. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J Hepatol 2010; 53: 348-356 [PMID: 20483498 DOI:10.1016/j.jhep.2010.02.035].
24. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI:10.1001/jama.295.1.65].
25. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006; 80: 1197-1213 [PMID: 16946019 DOI:10.1189/jlb.0506297].
26. Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19: 8822-8830 [PMID: 24379605 DOI:10.3748/wjg.v19.i47.8822].
27. Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 2001; 34: 593-602 [PMID: 11394661].
28. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-Analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077 [PMID: 18657133 DOI:10.1111/j.1365-2036.2008.03816.x].
29. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: A meta-Analysis. J Viral Hepat 2009; 16: 265-271 [PMID: 19220736 DOI:10.1111/j.1365-2893.2009.01070.x].
30. Miyake Y, Kobashi H, Yamamoto K. Meta-Analysis: The effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009; 44: 470-475 [PMID: 19308310 DOI:10.1007/s00535-009-0024-z].
31. Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-Analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106 [PMID: 23713520 DOI:10.1111/apt.12344].
32. Tillmann HL, Patel K. Therapy of acute and fulminant hepatitis B. Intervirology 2014; 57: 181-188 [PMID: 25034486 DOI:10.1159/000360939].
33. Polson J, Lee WM. AASLD Position paper: The management of acute liver failure. Hepatology 2005; 41: 1179-1197 [PMID: 15841455 DOI:10.1002/hep.20703].
34. Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: To treat or not to treat or when to treat? Liver Int 2012; 32: 544-553 [PMID: 22099371 DOI:10.1111/j.1478-3231.2011.02682.x].
35. Diamanti A, Sartorelli MR, Alterio A, Comparcola D, Corsetti T, Iacono A, Pizzichemi G, Nobili V, de Ville de Goyet J, Torre G. Successful tenofovir treatment for fulminant hepatitis B infection in an infant. Pediatr Infect Dis J 2011; 30: 912-914 [PMID: 21606886 DOI:10.1097/INF.0b013e31821e23b3].
36. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y. Nucleoside analogues improve the short-Term and long-Term prognosis of patients with hepatitis B virus-related acute-onchronic liver failure. Clin Exp Med 2012; 12: 159-164 [PMID: 22002708 DOI:10.1007/s10238-011-0160-7].
37. Burra P, Germani G, Adam R, Karam V, Marzano A, Lampertico P, Salizzoni M, Filipponi F, Klempnauer JL, Castaing D, Kilic M, Carlis LD, Neuhaus P, Yilmaz S, Paul A, Pinna AD, Burroughs AK, Russo FP. Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. J Hepatol 2013; 58: 287-296 [PMID: 23099188 DOI:10.1016/j.jhep.2012.10.016].
38. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847 [PMID: 8247035 DOI:10.1056/NEJM199312163292503].
39. Xu X, Tu Z, Wang B, Ling Q, Zhang L, Zhou L, Jiang G, Wu J, Zheng S. A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. Liver Int 2011; 31: 1477-1484 [PMID: 21745275 DOI:10.1111/j.1478-3231.2011.02500.x].
40. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215 [PMID: 8898039].
41. Katz LH, Tur-Kaspa R, Guy DG, Paul M. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane Database Syst Rev 2010; (7): CD006005 [PMID: 20614442 DOI:10.1002/14651858.CD006005.pub2].
42. Wang P, Tam N, Wang H, Zheng H, Chen P, Wu L, He X. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-Analysis. Plos One 2014; 9: E104480 [PMID: 25102072 DOI:10.1371/journal.pone.0104480].
43. Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, Akriviadis E. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int 2014; 27: 1022-1028 [PMID: 24909714 DOI:10.1111/tri.12370].
44. Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation 2014; 97 Suppl 8: S53-S59 [PMID: 24849836 DOI: 10.1097/01. tp.0000446278.43804.f9].
45. Chang MS, Stiles JB, Lukose TS, Balducci A, Brubaker WD, Burman BE, Emond JC, Brown RS. Adherence to hepatitis B immunoglobulin (HBIG) after liver transplantation. Transplantation 2013; 96: E84-e85 [PMID: 24296609 DOI:10.1097/01.TP.0000435696.23525.d0].
46. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013; 19: 268-274 [PMID: 23447403 DOI:10.1002/lt.23600].
47. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626 [PMID: 2010156].
48. Sánchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, Cirera I, Sánchez-Tapias JM, Rodés J. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501 [PMID: 10655276 DOI:10.1002/hep.510310233].
49. Al Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64: 926-928 [PMID: 9326423].
50. Cholongitas E, Vasiliadis T, Goulis I, Fouzas I, Antoniadis N, Papanikolaou V, Akriviadis E. Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat 2015; 22: 574-580 [PMID: 25385239 DOI:10.1111/jvh.12362].
51. Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: Real world experience. Clin Microbiol Infect 2015; Epub ahead of print [PMID: 26055419 DOI:10.1016/j.cmi.2015.05.035].
52. Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, Maynard M, Bailly F, Zoulim F, Cotte L. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate. J Viral Hepat 2013; 20: 650-657 [PMID: 23910650 DOI:10.1111/jvh.12088].
53. Lee KH, Wai CT, Lim SG, Manjit K, Lee HL, Da Costa M, Quak SH, Tan KC. Risk for de novo hepatitis B from antibody to hepatitis B core antigen-positive donors in liver transplantation in Singapore. Liver Transpl 2001; 7: 469-470 [PMID: 11349271 DOI:10.1002/lt.500070514].
54. Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, Shakil O, Fung JJ, Vargas HE. Impact of antihepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002; 73: 1598-1602 [PMID: 12042646].
55. Bortoluzzi I, Gambato M, Albertoni L, Mescoli C, Pacenti M, Cusinato R, Germani G, Senzolo M, Rugge M, Boccagni P, Zanus G, Cillo U, Burra P, Russo FP. Use of grafts from anti-HBc-positive donors in liver transplantation: A 5-year, single-center experience. Transplant Proc 2013; 45: 2707-2710 [PMID: 24034028 DOI:10.1016/j.transproceed.2013.07.049].
56. Xie M, Rao W, Yang T, Deng Y, Zheng H, Pan C, Liu Y, Shen Z, Jia J. Occult hepatitis B virus infection predicts de novo hepatitis B infection in patients with alcoholic cirrhosis after liver transplantation. Liver Int 2015; 35: 897-904 [PMID: 24750566 DOI:10.1111/liv.12567].
57. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: A systematic review. J Hepatol 2010; 52: 272-279 [PMID: 20034693 DOI:10.1016/j.jhep.2009.11.009].
58. Brock GN, Mostajabi F, Ferguson N, Carrubba CJ, Eng M, Buell JF, Marvin MR. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int 2011; 24: 570-581 [PMID: 21401727 DOI:10.1111/j.1432-2277.2011.01236.x].
59. Liao B, Zhang F, Lin S, He H, Liu Y, Zhang J, Xu Y, Yi J, Chen Y, Liu H, Wang Z, Cai W. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: A retrospective crosssectional study in Guangdong, China. Plos One 2014; 9: E115888 [PMID: 25532128 DOI:10.1371/journal.pone.0115888].
60. Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol 2015; 63: 1238-1253 [PMID: 26150256 DOI:10.1016/j.jhep.2015.06.026].
61. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-1383.e1 [PMID: 22537446 DOI:10.1053/j.gastro.2012.02.011].
62. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-1762 [PMID: 22821361 DOI:10.1002/hep.25976].
63. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396 [PMID: 12927925].
64. Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del- Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-728 [PMID: 19217183 DOI:10.1016/j.jhep.2008.11.015].
65. Verna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. High post-Transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int 2015; 35: 510-517 [PMID: 24905624 DOI:10.1111/liv.12616].
66. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud- Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-441 [PMID: 23669289 DOI:10.1016/j.jhep.2013.04.035].
67. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236 [PMID: 25911336 DOI:10.1016/j.jhep.2015.03.025].
68. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study. Gastroenterology 2015; 148: 100-107.e1 [PMID: 25261839 DOI:10.1053/j.gastro.2014.09.023].
69. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, De Jesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014; 384: 1756-1765 [PMID: 25078309 DOI:10.1016/S0140-6736(14)61036-9].
70. Dieterich D, Bacon BR, Flamm SL, Kowdley KV, Milligan S, Tsai N, Younossi ZM, Lawitz E. Evaluation of Sofosbuvir and Simeprevir - based regimens in TRIO network: Academic and community treatment of real-world, heterogeneous population. AASLD; 2014 Sep 7-11; Boston, MA, USA.
71. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493 [PMID: 24725238 DOI:10.1056/NEJMoa1316366].
72. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898 [PMID: 24725239 DOI:10.1056/NEJMoa1402454].
73. Bourliere M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Hyland RH, Ding X, Yang JC, Knox SJ, Pang PS, Subramanian GM, Symonds WT, McHutchison JG, Mangia A, Gane E, Reddy KR, Mikokamoii M, Pol S, Afdhal N. An Integrated Safety and Efficacy Analysis of > 500 Patients with Compensated Cirrhosis Treated with Ledipasvir/Sofosbuvir with or without Ribavirin. AASLD; 2014 Sep 7-11; Boston, MA, USA.
74. Flamm SL, Everson G, Charlton M, Denning J, Arterbrun S, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in Patients with Decompensated Cirrhosis: Preliminary Results of a Prospective, Multicenter Study. 2014 Sep 7-11; Boston, MA, USA.
75. Manns MP, Forns X, Samuel D, Denning J, Arterbrun S, Brandt- Sarif T, Dvory-Sobol H, Pang PS, McHutchison JG, Gane E, Mutimer D. Ledipasvir/Sofosbuvir with Ribavirin is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients with HCV Infection: Preliminary results of The Preospective SOLAR 2 Trial. EASL; 2015 Apr 22-26; Vienna, Austria.
76. Poordad F, Schiff E, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV patients with Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study. EASL; 2015 Apr 22-26; Vienna, Austria.
77. Ruiz I, Feray C, Pawlotsky JM, Hézode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl 2015; 21: 408-409 [PMID: 25420476 DOI:10.1002/lt.24051].
78. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673-684 [PMID: 10782918].
79. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS, Contos MJ, Coterell A, Maluf D, Posner MP, Fisher RA. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975-983 [PMID: 17600360 DOI:10.1002/lt.21117].
80. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830-836 [PMID: 15519657 DOI:10.1016/j.jhep.2004.06.029].
81. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896 [PMID: 11910340].
82. Carrión JA, Torres F, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010; 51: 23-34 [PMID: 19839063 DOI:10.1002/hep.23240].
83. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, Reed AI, Hemming AW, Liu C, Crawford JM, Nelson DR. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247 [PMID: 15376304 DOI:10.1002/lt.20238].
84. Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, Bruguera M, García-Valdecasas JC, Bosch J, Navasa M. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492-499 [PMID: 16496308 DOI:10.1002/hep.21090].
85. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687 [PMID: 18294165 DOI:10.1111/j.1600-6143.2007.02126.x].
86. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599 [PMID: 16827859 DOI:10.1111/j.1600-6143.2006.01362.x].
87. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, Leandro G, Patch D, Burroughs A. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-Analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709 [PMID: 18673428 DOI:10.1111/j.1365-2893.2008.01019.x].
88. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132: 1746-1756 [PMID: 17484872 DOI:10.1053/j.gastro.2007.03.041].
89. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londoño MC, Habersetzer F. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-1494 [PMID: 25557906 DOI:10.1002/hep.27681].
90. Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim KJ, Morelli G, Feld JJ, Brown RS, Frazier LM, Fried MW, Nelson D, Jacobson IM. Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + Ribavirin in Patients with Genotype 1: Interim Results of a Prospective, Observational Study. Hepatology 2014; 60 (S1): 660A.
91. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J Hepatol 2014; 60: 78-86 [PMID: 23994384 DOI:10.1016/j.jhep.2013.08.018].
92. Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; 61: 508-514 [PMID: 24801415 DOI:10.1016/j.jhep.2014.04.037].
93. Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117 [PMID: 25304641 DOI:10.1053/j.gastro.2014.10.001].
94. Reddy KR, Everson G, Flamm SL, Denning J, Arterbrun S, Brandt-Sarif T, Pang PS, McHutchison JG, Curry MP, Charlton M. Ledipasvir/Sofosbuvir with Ribavirin for the Treatment of HCV in patients with Post Trasplant Recurrence: Preliminary results of a Prospective, Multicenter Study. AASLD; 2014 Sep 7-11; Boston, MA, USA.
95. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886 [PMID: 25722203 DOI:10.1002/hep.27770].
96. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382 [PMID: 25386767 DOI:10.1056/NEJMoa1408921].
97. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, Botta D, Durand F, Silvain C, Lebray P, Houseel-Debry P, Kamar N, D'Alteroche L, Calmus Y, Bertucci I, Pageaux GP, Duclos-Vallee JC. High rates of virological response and major clinical improvement during Sofosbuvir and Daclatasvir- based regimens for the treatment of fibrosing cholestatic hepatitis HCVrecurrence after liver transplantation: The ANRS CO23 CUPILT Study. AASLD; 2014 Sep 7-11; Boston, MA, USA.
98. Fontana RJ, Herzer K, Ferenci P, Moreno A, Bahirwani R, Brown RS, Chacko K, Durand CM, Lionetti R, Loiacono M, Joshi S, Knop V, Londono MC, Montalbano M, Pellicelli AM, Mubarak A, Reddy KR, Berg CP. High Efficacy and Favorable Safety Profile of Daclatasvir based all oral antiviral therpay in Liver Transplant recipients with severe HCV recurrent. AASLD; 2014 Sep 7-11; Boston, MA, USA.
99. Londono MC, Herzer K, Moreno C, Elsharkawy AM, Sterneck M, Torti C, Clausen M, Andreone P, Herrero JI, Degre D, Pisani V, Vukotic R, Forns X. Safety and Efficacy of Simeprevir in combination with Daclatasvir or Sofosbuvir in patients with severe hepatitis C recurrence after liver transplantation: Results from the Compassionate Use in Europe. AASLD; 2014 Sep 7-11; Boston, MA, USA.